Skip to main content
PLOS One logoLink to PLOS One
. 2021 Jul 30;16(7):e0254261. doi: 10.1371/journal.pone.0254261

Characteristics of aspiration pneumonia patients in acute care hospitals: A multicenter, retrospective survey in Northern Japan

Jun Suzuki 1, Ryoukichi Ikeda 1,*, Kengo Kato 1, Risako Kakuta 1, Yuta Kobayashi 1, Akira Ohkoshi 1, Ryo Ishii 1, Ai Hirano-Kawamoto 1, Jun Ohta 1, Rei Kawata 2, Tomonori Kanbayashi 1, Masaki Hatano 1, Tadahisa Shishido 1, Yuya Miyakura 3, Kento Ishigaki 4, Yasunari Yamauchi 5, Miho Nakazumi 6, Takuya Endo 7, Hiroki Tozuka 8, Shiori Kitaya 2, Yuki Numano 6, Shotaro Koizumi 4, Yutaro Saito 2, Mutsuki Unuma 4, Ken Hashimoto 7, Eiichi Ishida 8, Toshiaki Kikuchi 8, Takayuki Kudo 3, Kenichi Watanabe 4, Masaki Ogura 5, Masaru Tateda 8, Takatsuna Sasaki 6, Nobuo Ohta 2, Tatsuma Okazaki 9, Yukio Katori 1
Editor: Michael J Lanspa10
PMCID: PMC8323917  PMID: 34329339

Abstract

Background

Pneumonia is a common cause of illness and death of the elderly in Japan. Its prevalence is escalating globally with the aging of population. To describe the latest trends in pneumonia hospitalizations, especially aspiration pneumonia (AP) cases, we assessed the clinical records of pneumonia patients admitted to core acute care hospitals in Miyagi prefecture, Japan.

Methods

A retrospective multi-institutional joint research was conducted for hospitalized pneumonia patients aged ≥20 years from January 2019 to December 2019. Clinical data of patients were collected from the medical records of eight acute care hospitals.

Results

Out of the 1,800 patients included in this study, 79% of the hospitalized pneumonia patients were aged above 70 years. The most common age group was in the 80s. The ratio of AP to total pneumonia cases increased with age, and 692 out of 1,800 patients had AP. In univariate analysis, these patients had significantly older ages, lower body mass index (BMI), a lower ratio of normal diet intake and homestay before hospitalization, along with more AP recurrences and comorbidities. During hospitalization, AP patients had extended fasting periods, more swallowing assessments and interventions, longer hospitalization, and higher in-hospital mortality rate than non-AP patients. A total of 7% and 2% AP patients underwent video endoscopy and video fluorography respectively. In multivariate analysis, lower BMI, lower C-reactive protein, a lower ratio of homestay before hospitalization, a higher complication rate of cerebrovascular disease, dementia, and neuromuscular disease were noted as a characteristic of AP patients. Swallowing interventions were performed for 51% of the AP patients who had been hospitalized for more than two weeks. In univariate analysis, swallowing intervention improved in-hospital mortality. Lower AP recurrence before hospitalization and a lower ratio of homestay before hospitalization were indicated as characteristics of AP patients of the swallowing intervention group from multivariate analysis. Change in dietary pattern from normal to modified diet was observed more frequently in the swallowing intervention group.

Conclusion

AP accounts for 38.4% of all pneumonia cases in acute care hospitals in Northern Japan. The use of swallowing evaluations and interventions, which may reduce the risk of dysphagia and may associate with lowering mortality in AP patients, is still not widespread.

1. Introduction

Pneumonia is a globally common infection and a major cause of death in adults [1, 2]. Its risks increase with age, and it is the main cause of hospitalization and mortality among the elderly [2, 3]. Review papers show that aspiration is strongly implicated in pneumonia in the elderly, and aspiration pneumonia (AP) is estimated to account for 5%-15% cases of community-acquired pneumonia (CAP), but the information of the rates of AP in hospital-acquired pneumonia (HAP) is limited [1, 4]. AP is a multi-factorial condition; impaired swallowing, abnormal cough reflex, host immune defense, and pathogen factors are intricately involved [1, 4]. The reported risk factors of AP are: age, male sex, dysphagia, diabetes mellitus, degenerative neurologic and lung diseases, impaired consciousness and dementia, dehydration, and use of antipsychotic drugs and proton pump inhibitors [59]. According to a report from Japan in 2008, the incidence of AP in CAP and HAP cases was 60.1% and 86.7%, respectively, and AP accounted for 66.8% of total hospitalized pneumonia patients [10]. The aging rate of the Japanese population (aged ≥65 years) was high at 28.1% in 2018, making Japan the world’s leading country in confronting healthcare problems of the elderly [11]. Pneumonia, including AP, was the third leading cause of death (9.7%) in Japan in 2018 [12]. The study that reported the high incidence of AP in CAP and HAP [10] was conducted a decade ago. The understanding of the relationship between AP and its risk factors, such as dysphagia, has recently improved. In addition, people in Japan have started to recognize AP as a common and fatal disease. Therefore, we believe that the ratio of AP has changed in the current social environment. Moreover, the epidemiology of pneumonia and the clinical features and outcomes of AP remain largely unknown.

In order to understand the current diagnosis and treatment of pneumonia in the elderly, we investigated (1) the incidence of hospitalized pneumonia according to age, (2) the rate of AP in hospitalized pneumonia patients, (3) the rate and characteristics of swallowing intervention-received pneumonia patients, (4) the occupations of the people who evaluated swallowing function and their methods, (5) evaluation of the effect of swallowing interventions on in-hospital mortality, (6) causative microorganisms in recent AP cases, and (7) the recent use of antibiotics, by assessing the clinical records of patients admitted to core acute care hospitals in Miyagi Prefecture, Japan, during the year 2019.

2. Materials and methods

2.1 Participants and data collection

A total of 1,800 pneumonia patients above 20 years of age, who were admitted to all the departments of (1) South Miyagi Medical Center (92 cases), (2) Tohoku University Hospital (107 cases), (3) Tohoku Rosai Hospital (278 cases), (4) Sendai City Hospital (149 cases), (5) Sendai Medical Center (78 cases), (6) Tohoku Medical and Pharmaceutical University Hospital (388 cases), (7) Osaki Citizen Hospital (289 cases), (8) Japanese Red Cross Ishinomaki Hospital (419 cases) in Miyagi Prefecture (Fig 1), Japan, between January 2019 and December 2019, were enrolled in the study. Miyagi prefecture has a total population of 2.3 million, including both urban (Sendai area: 1.5 million people) and rural zones (Sennan area: 180,000 people, Osaki/Kurihara area: 270,000 people, Ishinomaki/Tome/Kesennuma area: 350,000 people, Fig 1). Acute care hospitals participating in this study were core general hospitals of each area with emergency departments. These hospitals provided medical services to patients with CAP, nursing- and healthcare-associated pneumonia (NHCAP), corresponding to health-care-associated pneumonia (HCAP) [13, 14], and HAP. Exclusion criteria were patients with interstitial pneumonia, fungal and/or acid-fast bacilli infection, acquired immunodeficiency syndrome (AIDS), and transplantation.

Fig 1. Localization of participating hospitals in Miyagi prefecture, Japan.

Fig 1

A: a map of Japan. B: a map of Miyagi Prefecture. (1) South Miyagi Medical Center, (2) Tohoku University Hospital, (3) Tohoku Rosai Hospital, (4) Sendai City Hospital, (5) Sendai Medical Center, (6) Tohoku Medical and Pharmaceutical University Hospital, (7) Osaki Citizen Hospital, (8) Japanese Red Cross Ishinomaki Hospital. A: Sennan area, B: Sendai area, C: Osaki/Kurihara area, D: Ishinomaki/Tome/Kesennuma area.

Clinical data including age, sex, body mass index (BMI), vital signs, laboratory data, comorbidities, residential and feeding status, microbiological examinations, use of antibacterial agents, alternative nutrition during hospitalization, swallowing assessments and interventions, and clinical outcomes were collected from medical records of each hospital. Clinical outcomes were evaluated by length of hospitalization and in-hospital mortality. This study was approved by the Tohoku University Hospital Institutional Review Board (IRB) (Reference number: 2019-1-971). All data were fully anonymized, and IRB in our institution waived the requirement for informed consent.

2.2 Criteria of pneumonia

Pneumonia was defined as an acute illness associated with the presence of new pulmonary infiltrates on chest radiograph and/or computed tomography (CT), along with at least two or three respiratory symptoms (cough, sputum production, wheezing, fever, and dyspnea) and inflammation determined by blood analyses of white blood cell (WBC) count and C-reactive protein (CRP). The diagnostic criteria for pneumonia were determined by a guideline from the Japan Respiratory Society. The definition of AP was based on that of the Japanese Study Group on Aspiration Pulmonary Disease: (1) pneumonia with an overt aspiration witnessed by surrounding persons; (2) pneumonia with a strongly suspected aspiration condition; (3) pneumonia with a predisposition to aspiration because of abnormal swallowing function or dysphagia, (4) compatible radiologic findings of aspiration pneumonia [15]. Pneumonia patients who did not meet the criteria were defined as patients with non-aspiration pneumonia (non-AP).

2.3 Definition of swallowing intervention

The Japanese Society of Dysphagia Rehabilitation described "Summaries of training methods in 2014" which contained 25 indirect and 13 direct exercises [16]. We categorized pneumonia patients who received one and more kinds of swallowing exercises into swallowing intervention group.

2.4 Microbiological and antibiotic studies

We defined CAP as pneumonia in patients at home before admission and NHCAP/HAP as pneumonia in patients in nursing homes or other hospitals and analyzed the microbiological and antibiotic characteristics of AP and non-AP patients in each CAP and NHCAP/HAP group. Standard microbiological procedures were performed for investigation of pathogens in two sets of blood and/or sputum samples. Antibody testing for Mycoplasma pneumoniae and Chlamydia pneumoniae and urinary antigen detection for Streptococcus pneumoniae and Legionella pneumophila was done, if indicated, by the attending physician. The number of antibiotics, if more than one was consumed, was counted.

2.5 Statistical analysis

The Student’s t-test, the Wilcoxon–Mann–Whitney test, or Fisher’s exact test was performed using statistical software SPSS version 27 (IBM, Chicago, IL, USA) or JMP Pro version 15 (SAS Institute Inc., Cary, NC, USA). Factors characterizing AP and swallowing intervention group were determined using logistic regression analysis with independent variables with presumed clinical importance by using JMP Pro version 15. Considering the covariance, we selected independent variables regarding factors characterizing aspiration pneumonia as follows: general status (age, sex); nutritional condition (BMI, diet before hospitalization); inflammation severity (C-reactive protein, SpO2); past medical history (cerebrovascular disease, dementia, neuromuscular disease); residential status; assessment and treatment (fasting, swallowing intervention); outcomes (length of hospitalization, mortality). Selected independent variables regarding factors characterizing swallowing intervention group were as follows: general status (age, sex); nutritional condition (BMI); inflammation severity (C-reactive protein, SpO2); past medical history (cerebrovascular disease, dementia, neuromuscular disease, AP recurrence); residential status; assessment and treatment (fasting, swallowing assessment); outcomes (length of hospitalization, mortality). Differences with a corrected p-value of less than 0.05 were considered significant. Data were presented as mean ± standard deviation.

3. Result

3.1 Aspiration pneumonia vs. non-aspiration pneumonia

Overall, 1,800 patients met the inclusion criteria and were included in this study (Fig 2). A total of 79% of the hospitalized pneumonia patients were aged above 70 years, and the most common age group was in the 80s (Fig 3A). The ratio of AP to total pneumonia cases increased with age (Fig 3B). Out of 1,419 pneumonia patients aged above 70 years, 607 patients (42.8%) were diagnosed with AP compared to 85 of 381 patients under 70 years of age (22.3%). Patient characteristics of both AP and non-AP groups are shown in Table 1. AP group had 692 cases (38.4%) and non-AP group had 1,108 cases (61.6%). The mean age was significantly higher in AP group compared with non-AP group. On the contrary, BMI, CRP, serum albumin, and oxygen saturation under room air measured at admission were significantly lower in AP group than in non-AP group. The rates of AP recurrences and comorbidities such as dementia, cerebrovascular, and neuromuscular diseases were significantly higher in AP group than in non-AP group.

Fig 2. A flow chart of patients evaluated throughout the course of this study.

Fig 2

Fig 3. The ratio of aspiration pneumonia to total pneumonia cases.

Fig 3

A: The number of hospitalized aspiration and non-aspiration pneumonia patients according to age. B: The percentages of aspiration and non-aspiration pneumonia patients in total hospitalized pneumonia patients according to age.

Table 1. Characteristics of patients with aspiration and non-aspiration pneumonia.

Aspiration pneumonia Non-aspiration pneumonia P Value
Patients 692 (38%) 1108 (62%)
Age 81.2 ±12.6 75.4 ±15.0 < 0.001
Sex (female) 251 (36%) 400 (36%) 0.861
Body mass index, mean ± SD 19.4 ±4.0 21.4 ±4.6 < 0.001
Body temperature 37.6 ±1.5 37.7 ±1.2 0.145
Laboratory data
Leukocyte counts 11119.5 ±6348.5 10552.6 ±5790.7 0.070
C-reactive protein (mg/dl) 9.4 ±8.5 11.5 ±9.8 < 0.001
Serum albumin (g/dl) 3.1 ±0.6 3.2 ±0.6 < 0.001
SpO2 breathing room air on admission 91.7 ±7.0 93.1 ±6.0 < 0.001
Comorbidity
Cancer 187 (27%) 314 (28%) 0.543
Cerebrovascular disease 206 (30%) 153 (14%) < 0.001
Dementia 270 (39%) 124 (11%) < 0.001
Neuromuscular disease 93 (13%) 34 (3%) < 0.001
Chronic respiratory disease 192 (28%) 418 (38%) < 0.001
AP recurrence case 240 (35%) 304 (27%) 0.002
Residential status before hospitalization
Home 471 (68%) 1003 (91%) < 0.001
The other hospital 53 (8%) 23 (2%) < 0.001
Nursing home 166 (23%) 73 (7%) < 0.001
Oral intake before hospitalization
Normal diet 397 (57%) 953 (86%) < 0.001
Modified diet 235 (34%) 119 (11%) < 0.001
Gastrostomy 38 (6%) 16 (1%) < 0.001
Nasogastric tube 14 (2%) 10 (1%) 0.042
Treatment, Evaluation, Intervention
Fasting 573 (83%) 410 (37%) < 0.001
Fasting period (day) 8.3 ±12.0 2.6 ±8.2 < 0.001
Alternative nutrition during hospitalization
Nasogastric tube 74 (11%) 39 (4%) < 0.001
Total parenteral nutrition 39 (6%) 40 (4%) 0.052
Peripheral parenteral nutrition 620 (90%) 692 (62%) < 0.001
Oral intake only 34 (5%) 316 (29%) < 0.001
Swallowing assessment 410 (59%) 294 (27%) < 0.001
Video Endoscopy 51 (7%) 19 (2%) < 0.001
Video fluorography 14 (2%) 3 (0%) 0.002
Speech therapist 245 (35%) 135 (12%) < 0.001
Nurse 275 (40%) 184 (17%) < 0.001
Swallowing intervention 264 (38%) 140 (13%) < 0.001
Speech therapist 225 (33%) 118 (11%) < 0.001
Nurse 21 (3%) 15 (1%) 0.023
Dentist 45 (7%) 28 (3%) < 0.001
Nutritional support team 76 (11%) 29 (3%) < 0.001
Outcomes
Length of hospitalization (day) 22.7 ±24.1 17.0 ±17.7 < 0.001
Mortality 119 (17%) 95 (9%) < 0.001
Oral intake at discharge
Normal diet 129 (23%) 684 (68%) < 0.001
Modified diet 273 (48%) 266 (26%) < 0.001
Gastrostomy 47 (8%) 21 (2%) < 0.001
Nasogastric tube 41 (7%) 17 (2%) < 0.001

SD; standard deviation, SpO2; saturation of percutaneous oxygen, AP; aspiration pneumonia

We divided diet into two types, normal diet or diet modified to help to swallow. The rates of normal diet intake and homestay before hospitalization were significantly lower in the AP group than in the non-AP group (Table 1). The AP group had a longer fasting period and a higher rate of alternative nutrient use, such as applying a nasogastric tube and parenteral nutrition than the non-AP group. Speech therapists and nurses mainly assessed dysphagia, and speech therapists and nutritional support teams mainly performed swallowing intervention in both AP and non-AP patients. Detailed swallowing evaluations through video endoscopy and videofluoroscopic evaluation were performed in 7% (51 cases) and 2% (14 cases) AP patients, respectively. Length of hospitalization and mortality rate was significantly higher in AP group than in the non-AP group (Table 1). At the time of discharge, 68% of non-AP patients took a normal diet, whereas only 23% of patients with AP took a normal diet (Table 1). Correspondingly, the rates of use of modified diet, gastrostomy, and nasogastric tube were significantly higher in patients with AP (total 63%) than in the non-AP patients (total 30%).

To reveal the characteristics of AP patients compared with non-AP patients, we performed a multivariate analysis. Logistic regression analysis showed that lower BMI, lower C-reactive protein, a lower ratio of homestay before hospitalization, a higher complication rate of cerebrovascular disease, dementia, and neuromuscular disease, more fasting controls, and more swallowing interventions were noted as a characteristic of AP patients (Table 2).

Table 2. Factors characterizing aspiration pneumonia by logistic regression analysis.

Coefficient SE P Value Odds ratio 95% CI
Constant -1.650 1.342
Age -0.010 0.006 0.079 1.010 0.999–1.022
Sex (female) 0.104 0.080 0.196 0.812 0.592–1.113
Body mass index 0.077 0.019 < .0001 0.926 0.891–0.961
C-reactive protein 0.021 0.009 0.015 0.979 0.962–0.996
SpO2 breathing room air on admission 0.001 0.012 0.946 0.999 0.975–1.023
Cerebrovascular disease -0.241 0.096 0.012 1.619 1.113–2.355
Dementia -0.434 0.098 < .0001 2.384 1.621–3.507
Neuromuscular disease -0.493 0.162 0.002 2.681 1.422–5.055
Residential status before hospitalization (home) -0.349 0.105 0.001 0.498 0.330–0.751
Fasting -0.744 0.083 < .0001 4.432 3.203–6.034
Swallowing intervention -0.508 0.093 < .0001 2.760 1.915–3.978
Length of hospitalization 0.000 0.003 0.962 1.000 0.993–1.001
Mortality -0.015 0.132 0.911 1.030 0.614–1.727

SE; standard error, 95%CI; 95% ofconfidence interval, SpO2; saturation of percutaneous oxygen, AP; aspiration pneumonia

3.2 Characteristics of swallowing intervention cases

Some patients with AP received swallowing interventions, while others did not (Table 1). In order to clarify the characteristics of AP patients with swallowing interventions, we also evaluated AP patients with hospitalization of 14 days and longer periods because it was difficult to evaluate the effect of swallowing interventions on short-time hospitalization cases. Patient characteristics of the swallowing intervention and non-swallowing intervention group were shown in Table 3. A total of 404 patients met the inclusion criteria, and 208 patients received swallowing interventions (51%). In the swallowing intervention group, the mean age and rate of patients with cerebrovascular disease were significantly higher, fasting period was longer, and oxygen saturation under room air, rate of patients with neuromuscular disease, and AP recurrence rate were significantly lower compared with non-swallowing intervention groups. Correspondingly, the rate of normal diet intake before hospitalization was significantly lower in the swallowing intervention group. The number of patients with the above three comorbidities was 157 in each group. Speech therapists mainly performed swallowing assessments and interventions in 86% of cases, including overlapping.

Table 3. Characteristics of aspiration pneumonia patients with swallowing interventions.

Swallowing intervention (+) Swallowing intervention (-) P Value
Patients 208 (51%) 196 (49%)
Age 83.3 ±9.9 79.5 ±12.4 < 0.001
Sex (female) 73 (35%) 67 (34%) 0.917
Body mass index, mean ± SD 19.2 ±4.1 18.8 ±4.2 0.292
Body temperature 37.6 ±2.0 37.7 ±1.2 0.629
Laboratory data
Leukocyte counts 10610.9 ±4704.9 10980.7 ±5830.9 0.923
C-reactive protein (mg/dl) 10.4 ±9.0 10.4 ±8.6 0.840
Serum albumin (g/dl) 3.0 ±0.6 3.1 ±0.6 0.595
SpO2 breathing room air on admission 90.6 ±8.3 92.9 ±5.5 0.008
Comorbidity
Cancer 54 (26%) 57 (29%) 0.483
Cerebrovascular disease 79 (38%) 48 (25%) 0.004
Dementia 88 (42%) 72 (37%) 0.253
Neuromuscular disease 22 (11%) 35 (18%) 0.038
Chronic respiratory disease 50 (24%) 58 (30%) 0.219
AP recurrence case 56 (27%) 74 (38%) 0.020
Residential status before hospitalization
Home 138 (66%) 136 (69%) 0.514
The other hospital 19 (9%) 17 (9%) 0.871
Nursing home 51 (25%) 41 (21%) 0.389
Oral intake before hospitalization
Normal diet 112 (54%) 130 (66%) 0.011
Modified diet 89 (43%) 46 (23%) < 0.001
Gastrostomy 3 (1%) 20 (10%) < 0.001
Nasogastric tube 7 (3%) 3 (1%) 0.230
Treatment, Evaluation, Intervention
Fasting 189 (91%) 164 (84%) 0.030
Fasting period (day) 13.3 ±16.4 10.1 ±11.8 0.024
Alternative nutrition during hospitalization
Nasogastric tube 35 (17%) 25 (13%) 0.251
Total parenteral nutrition 25 (12%) 12 (6%) 0.040
Peripheral parenteral nutrition 199 (96%) 174 (89%) 0.009
Oral intake only 4 (2%) 12 (6%) 0.031
Swallowing assessment 200 (96%) 78 (40%) < 0.001
Video Endoscopy 41 (20%) 6 (3%) < 0.001
Video fluorography 11 (5%) 3 (1%) 0.004
Speech therapist 178 (86%) 15 (8%) < 0.001
Nurse 111 (53%) 58 (30%) < 0.001
Swallowing intervention 208 (100%) 0 (0%) < 0.001
Speech therapist 179 (86%) 0 (0%) < 0.001
Nurse 16 (8%) 0 (0%) < 0.001
Dentist 38 (18%) 0 (0%) < 0.001
Nutritional support team 66 (32%) 0 (0%) < 0.001
Outcomes
Length of hospitalization (day) 34.7 ±25.9 32.3 ±27.5 0.026
Mortality 17 (8%) 31 (16%) 0.018
Oral intake at discharge
Normal diet 18 (9%) 48 (29%) < 0.001
Modified diet 120 (63%) 67 (41%) < 0.001
Gastrostomy 10 (5%) 23 (14%) 0.005
Nasogastric tube 20 (10%) 15 (9%) 0.663

SD; standard deviation, SpO2; saturation of percutaneous oxygen, AP; aspiration pneumonia

Detailed swallowing evaluations through video endoscopy and video fluorography were performed in 20% (41 cases) and 5% (11 cases) of patients with swallowing intervention, respectively. Regarding outcomes of patients, although fasting periods and lengths of hospitalization were significantly longer, mortality was significantly lower in the swallowing intervention group (8% vs. 16%, p = 0.0178).

To reveal the characteristics of swallowing intervention cases, we performed a multivariate analysis. Logistic regression analysis showed that a lower ratio of AP recurrence, a lower ratio of homestay before hospitalization, a higher rate of swallowing assessments were noted as characteristics of swallowing intervention cases in AP patients (Table 4).

Table 4. Factors characterizing swallowing intervention group by logistic regression analysis.

Coefficient SE P Value Odds ratio 95% CI
Constant -0.780 3.255
Age -0.029 0.018 0.097 1.030 0.995–1.067
Sex (female) 0.018 0.182 0.920 0.964 0.472–1.970
Body mass index 0.067 0.047 0.154 0.935 0.852–1.026
C-reactive protein 0.001 0.021 0.946 0.999 0.959–1.040
SpO2 breathing room air on admission 0.031 0.028 0.269 0.970 0.999–1.031
Cerebrovascular disease 0.266 0.196 0.175 1.702 0.789–3.670
Dementia -0.101 0.193 0.602 0.817 0.383–1.744
Neuromuscular disease 0.050 0.305 0.870 1.105 0.334–3.658
AP recurrence case -0.562 0.184 0.002 0.325 0.158–0.670
Residential status before hospitalization (home) -0.429 0.208 0.039 0.424 0.188–0.959
Normal diet before hospitalization -0.266 0.192 0.166 0.587 0.277–1.248
Fasting -0.471 0.292 0.106 0.390 0.124–1.223
Swallowing assessment 2.002 0.308 < .0001 54.840 16.389–183.506
Length of hospitalization -0.015 0.008 0.063 1.015 0.999–1.031
Mortality -0.001 0.300 0.999 0.999 0.308–3.243

SE; standard error, 95%CI; 95% ofconfidence interval, SpO2; saturation of percutaneous oxygen, AP; aspiration pneumonia

From the swallowing intervention and non-swallowing intervention group, a total of 112 (54%) and 130 (66%) patients respectively had a normal diet intake before hospitalization, and 16 (14%) and 44 (34%) patients respectively had a normal diet intake at the time of discharge (Table 5).

Table 5. The rate of normal diet intake in initially normal diet-taking aspiration pneumonia patients after swallowing interventions.

Normal diet Modified diet No oral intake / Unknown Death
Swallowing intervention (+) 16 (14.3%) 64 (57.1%) 23 (20.5%) 9 (8.0%)
Swallowing intervention (-) 44 (33.8%) 43 (33.1%) 20 (15.4%) 23 (17.7%)

3.3 Causative organisms and choice of antibiotics

There were significant differences between the causative organisms of the AP and non-AP groups in CAP, with a higher frequency of Staphylococcus aureus, Klebsiella spp., and Escherichia coli, and a lower frequency of S. pneumoniae, and Haemophilus influenzae in the AP group (Table 6). The detection rate of anaerobic bacteria, e.g., Bacteroides spp., Prevotella spp., and Fusobacterium spp. was low in both groups.

Table 6. Pathogen distribution in community-acquired pneumonia (CAP).

CAP Aspiration pneumonia Non-aspiration pneumonia (n = 1003) P value
(n = 471)
N N
Streptococcus pneumoniae 38 8.2% 152 15.3% < 0.001
penicillin-susceptible 34 121
penicillin-resistant 2 6
Staphylococcus aureus 91 19.7% 100 10.1% < 0.001
methicillin-susceptible 59 67
methicillin-resistant 32 33
Pseudomonas aeruginosa 27 5.8% 37 3.7% 0.075
Klebsiella spp. 76 16.4% 60 6.0% < 0.001
ESBL 5 4
Non-ESBL 63 45
Escherichia coli 30 6.5% 30 3.0% 0.003
ESBL 11 6
Non-ESBL 19 19
Haemophilus influenzae 21 4.5% 81 8.2% 0.011
BLNAS 4 19
BLPAR 2 8
BLNAR 10 21
BLPACR 0 4
Moraxella catarrhalis 12 2.6% 30 3.0% 0.738
Proteus spp. 3 0.6% 4 0.4% 0.686
ESBL 0 1
Non-ESBL 3 2
Mycoplasma pneumoniae 1 0.2% 1 0.1% 0.535
Legionella spp. 2 0.4% 12 1.2% 0.248
Bacteroides spp. 2 0.4% 1 0.1% 0.239
Prevotella spp. 0 0.0% 2 0.2% 1.000
Fusobacterium spp. 0 0.0% 1 0.1% 1.000
Others 58 12.5% 149 15.0% 0.227
Unknown 191 41.3% 444 44.8% 0.195

ESBL; Extended spectrum β-lactamase, BLNAS; β-lactamase non-producing ampicillin susceptible, BLPAR; β-lactamase producing ampicillin resistant, BLNAR; β- lactamase-non-producing ampicillin-resistance, BLPACR; β-lactamase producing amoxicillin/clavulanic acid resistant.

In HNCAP/HAP, there were no significant differences between AP and non-AP groups as to the causative organisms (Table 7).

Table 7. Pathogen distribution in nursing- and healthcare-associated pneumonia and hospital-acquired pneumonia (NHCAP/HAP).

NHCAP/HAP Aspiration pneumonia Non-aspiration pneumonia P value
(n = 219) (n = 96)
N N
Streptococcus pneumoniae 19 8.8% 12 12.6% 0.309
penicillin-susceptible 18 7
penicillin-resistant 0 2
Staphylococcus aureus 59 27.3% 18 18.9% 0.120
methicillin-susceptible 22 5
methicillin-resistant 37 13
Pseudomonas aeruginosa 22 10.2% 5 5.3% 0.192
Klebsiella spp. 26 12.0% 11 11.6% 1.000
ESBL 1 1
Non-ESBL 17 7
Escherichia coli 20 9.3% 7 7.4% 0.667
ESBL 11 6
Non-ESBL 8 0
Haemophilus influenzae 6 2.8% 3 3.2% 1.000
BLNAS 1 1
BLPAR 1 1
BLNAR 2 0
BLPACR 1 0
Moraxella catarrhalis 6 2.8% 1 1.1% 0.680
Proteus spp. 4 1.9% 0 0.0% 0.317
ESBL 2 0
Non-ESBL 2 0
Mycoplasma pneumoniae 0 0.0% 0 0.0% 1.000
Legionella spp. 1 0.5% 0 0.0% 1.000
Bacteroides spp. 1 0.5% 0 0.0% 1.000
Prevotella spp. 0 0.0% 0 0.0% 1.000
Fusobacterium spp. 0 0.0% 0 0.0% 1.000
Others 20 9.3% 13 13.7% 0.239
Unknown 78 36.1% 38 40.0% 0.612

ESBL; Extended spectrum β-lactamase, BLNAS; β-lactamase non-producing ampicillin susceptible, BLPAR; β-lactamase producing ampicillin resistant, BLNAR; β- lactamase-non-producing ampicillin-resistance, BLPACR; β-lactamase producing amoxicillin/clavulanic acid resistant.

In CAP, the most frequent empirical antibiotic treatment in AP group was Sulbactam / Ampicillin (SBT/ABPC) (64.5% in AP group vs. 36.5% in non-AP group, p<0.001). Clindamycin (3.2% vs 0.8%, p = 0.001) was also more frequently used in AP group. Conversely, Ceftriaxone (CTRX) (20.0% vs. 37.3%, p<0.001) was more frequently used in non-AP group. Levofloxacin (LVFX) (4.0% vs. 11.1%, p<0.001) was also more frequently used in non-AP group (Table 8).

Table 8. Selection of antibiotics in community-acquired pneumonia (CAP).

CAP Aspiration pneumonia Non-aspiration pneumonia P Value
(n = 470) (n = 986)
N % N %
Ampicillin 3 0.6% 7 0.7% 1.000
Penicillin G 0 0.0% 1 0.1% 1.000
Sulbactam / Ampicillin 303 64.5% 360 36.5% < 0.001
Piperacillin 5 1.1% 12 1.2% 1.000
Tazobactam / Piperacillin 56 11.9% 142 14.4% 0.220
Cefotaxime 0 0.0% 6 0.6% 0.186
Ceftriaxone 94 20.0% 368 37.3% < 0.001
Cefotiam 1 0.2% 1 0.1% 0.542
Imipenem / Cilastatin 0 0.0% 1 0.1% 1.000
Meropenem 20 4.3% 63 6.4% 0.116
Panipenem / Betamipron 0 0.0% 0 0.0% 1.000
Biapenem 1 0.2% 2 0.2% 1.000
Levofloxacin 19 4.0% 109 11.1% < 0.001
Ciprofloxacin 0 0.0% 4 0.4% 0.312
Pazufloxacin 1 0.2% 0 0.0% 0.323
Minocycline 4 0.9% 28 2.8% 0.013
Clindamycin 15 3.2% 8 0.8% 0.001
Vancomycin 5 1.1% 8 0.8% 0.767
Linezolid 2 0.4% 0 0.0% 0.104
Amikacin 0 0.0% 1 0.1% 1.000
Sulfamethoxazole—Trimethoprim 0 0.0% 5 0.5% 0.182

In NHCAP/HAP, there were no significant differences between AP and non-AP groups as to the selection of antibiotics: SBT/ABPC, CTRX, and Tazobactam/Piperacillin were frequently used in both groups (Table 9).

Table 9. Selection of antibiotics in nursing- and healthcare-associated pneumonia and hospital-acquired pneumonia (NHCAP/HAP).

NHCAP/HAP Aspiration pneumonia (n = 212) Non-aspiration pneumonia (n = 96) P Value
N % N %
Ampicillin 2 0.9% 1 1.0% 1.000
Penicillin G 0 0.0% 1 1.0% 0.323
Sulbactam / Ampicillin 123 58.0% 48 47.5% 0.216
Piperacillin 2 0.9% 2 2.0% 0.597
Tazobactam / Piperacillin 38 17.9% 12 11.9% 0.249
Cefotaxime 2 0.9% 0 0.0% 1.000
Ceftriaxone 40 18.9% 26 25.7% 0.133
Cefotiam 1 0.5% 0 0.0% 1.000
Imipenem / Cilastatin 0 0.0% 0 0.0% 1.000
Meropenem 19 9.0% 3 3.0% 0.060
Panipenem / Betamipron 0 0.0% 0 0.0% 1.000
Biapenem 0 0.0% 0 0.0% 1.000
Levofloxacin 3 1.4% 4 4.0% 0.210
Ciprofloxacin 0 0.0% 0 0.0% 1.000
Pazufloxacin 0 0.0% 0 0.0% 1.000
Minocycline 1 0.5% 5 5.0% 0.015
Clindamycin 6 2.8% 2 2.0% 1.000
Vancomycin 2 0.9% 4 4.0% 0.088
Linezolid 1 0.5% 0 0.0% 1.000
Amikacin 0 0.0% 0 0.0% 1.000
Sulfamethoxazole–Trimethoprim 1 0.5% 1 1.0% 0.542

4. Discussion

In this study, we evaluated 1,800 hospitalized pneumonia patients in acute care hospitals. A total of 79% of the hospitalized patients with pneumonia were above 70 years of age, and the most common age group was in the 80s. From the univariate analyses, we revealed as follows: (1) AP patients showed significantly older ages, lower BMI, more numbers of comorbidities, more AP recurrences, lesser normal diet intake, and lesser homestay before hospitalization compared with non-AP patients; (2) patients with AP had more extended fasting periods, more swallowing assessment and intervention rates, longer hospitalization, and higher in-hospital mortality rate during hospitalization. Multivariate analyses showed that lower BMI, lower C-reactive protein, a lower ratio of homestay before hospitalization, a higher complication rate of cerebrovascular disease, dementia, and neuromuscular disease were significant characteristics of AP patients. These results might reflect the current situation of hospitalized pneumonia in acute care hospitals in Japan, the country possessing the most aged society in the world.

4.1 AP in aged society

We showed that AP accounts for 38.4% (692 in 1,800) of all hospitalized pneumonia cases, including those of CAP, NHCAP, and HAP, and 42.8% (607 in 1,419) cases in the elderly (aged ≥70 years). As seen in a previous report [10], this study also shows that the rate of AP among total pneumonia cases increases with age in patients above 70 years (Fig 1B). AP comprises 22.3% of pneumonia patients under 70 years of age. This result might be due to the inclusion of young patients with severe complications such as malignancies, neuromuscular, and respiratory diseases. The presence of these patients may reflect the current situation of acute care hospitals.

In this study, the most common age group for AP was in the ’80s (Fig 1A), and this peak of age group had shifted 10 years older compared with the previous report from Japan [10]. Since aging is accompanied by the onset of pneumonia [17], this result might reflect the dramatic increase in the number of aged people (≥65 years) from 28.22 million (22.1% of the total population in Japan) in 2008 to 35.56 million (28.1%) in 2018.

Compared to the result of a study in 2008 that shows that AP accounts for 66.8% (394 in 589) of all pneumonia cases, and 80.1% (306 in 382) of elderly pneumonia cases (aged ≥70 years) [10], the percentage of AP cases in our study (38.4% and 42.8%, respectively) was apparently low. Recent studies from Japan reported that the prevalences of AP were 18.2% (adult) [18], 46.7% (aged ≥15 years) [19], and 50.4% (aged ≥70 years) [20]. Although robust diagnostic criteria for AP are lacking and surveys on AP consequently include heterogeneous patient populations [1], these results imply that the prevalence of AP has fallen over the last decade. This phenomenon might be partly caused by the increased awareness of dysphagia that can result in AP. Thus, the current medical personnel might be more aware of AP than those a decade ago. In fact, in acute care hospitals in Miyagi prefecture, the number of swallowing evaluations in 2019 was greater than those in the middle of the 2000 decade because of the change in the otolaryngology system in this region. These changes may reduce the ratio of AP in total pneumonia in older people.

4.2 Clinical features and outcomes of AP

Aspiration is widely recognized as an important risk factor for pneumonia [21], and dysphagia affects up to 60% of the institutionalized elderly population [2224]. However, there are limited data on the clinical characteristics of AP available at present [8, 9, 19, 25]. Using systematic literature review, van der Maarel-Wierink et al. identified 13 risk factors of AP: age, male sex, lung diseases, dysphagia, diabetes mellitus, dementia, angiotensin I-converting enzyme deletion/deletion genotype, bad oral health, malnutrition, Parkinson’s disease, and the use of antipsychotic drugs, proton pump inhibitors, and angiotensin-converting enzyme inhibitors [9]. Accordingly, in this study, the patients with AP were older and showed a greater prevalence of dementia, neuromuscular diseases, and malnutrition than non-AP patients. We diagnosed malnutrition by low BMI and low serum albumin. Other observational studies indicated many potential risk factors of AP [8, 19, 25, 26]; decrease in BMI, and presence of confusion (dementia), cerebrovascular and neuromuscular disease was also confirmed from the multivariate analysis in our study. Compared with non-AP patients, AP patients in this study had a more extended hospitalization and a higher in-hospital mortality rate. These results were consistent with previous reports [19, 25, 27]. A recent systematic review of AP patients with CAP also suggests that AP is associated with both higher in-hospital and 30-day mortality rates in CAP patients outside the intensive care unit [28]. A number of aspiration risk factors, e.g., dementia, poor performance status, and sleeping drugs, are associated with a rise in mortality and recurrence of pneumonia in the elderly [8]. Future multicenter prospective studies will be needed to identify new risk factors for AP.

4.3 Swallowing assessment and intervention of hospitalized pneumonia patients

The recurrence of pneumonia is characteristic of AP [19, 25, 27]. Considering this fact, many AP patients had modified diets or gastric gavage feedings before hospitalization. In this study, swallowing evaluations were performed for 59.2% (410/692 cases) of AP patients, and 39.1% (704/1,800 cases) of total pneumonia patients. Speech-language pathologists and nurses mainly performed swallowing evaluations. Otolaryngologists mainly performed video endoscopy and videofluoroscopic evaluation in 7% of AP patients and 2% of non-AP patients. Recent reports showed that risk-adjusted mortality of AP patients is lower in hospitals reporting a high frequency of AP than in hospitals reporting a low frequency of AP [27]. It must be important to pick up appropriate candidates for swallowing assessments to find undiagnosed dysphagia patients.

4.4 Effects of swallowing intervention

Among AP patients who were hospitalized for more than two weeks, 51% of the patients received swallowing interventions (208/404 patients). Patients in the swallowing intervention group had older ages, longer fasting periods and hospitalization, but had a significantly lower mortality rate than those in the non-intervention group in the univariate analyses. However, the multivariate analysis did not support these results. Since this study was a retrospective cross-sectional study, future studies are required to investigate the effects of swallowing intervention on the outcomes of AP patients.

The present study revealed that swallowing interventions significantly changed the dietary pattern from a normal diet to a modified diet. Malnutrition is common in elderly people, especially those with chronic disorders [29], and is associated with poor hospitalization outcomes [30]. Modified diets have been considered to decrease mis-swallowing [31, 32] and improve the nutrient intake of institutionalized elderly [24]. On the contrary, Wright et al. reported that the elderly patients on a texture-modified food diet have a lower intake of energy and protein than those taking a normal hospital diet [33]. Although research backgrounds were different in these studies, appropriate swallowing assessments and nutritional management will be necessary to induce modified foods.

4.5 Causative organisms of AP and treatments

Based on the studies in the 1970s, anaerobic organisms were presumed to predominantly cause AP [34, 35]. Because the previous studies often performed trans-tracheal sampling and assessed patients late in their clinical course [4, 34, 35], the contribution of anaerobes in AP had been overestimated. Nowadays, the concept of AP has changed, and the involvement of anaerobic bacteria in CAP and HAP is considered to be smaller than expected. The usual causative organisms of CAP, e.g., S. pneumoniae and S. aureus, are thought to play a major role in AP etiology [3638]. In accordance with previous studies, causative organisms in our AP patients in CAP were S. aureus (19.7%) and Klebsiella spp. (16.4%), and typical anaerobes of AP, e.g., Fusobacterium spp. and Bacteroides spp., were rare in this study. In NHCAP/HAP, causative organisms were not significantly different between AP and non-AP patients. This result may reflect the possibility that AP may be included in the category of non-AP in NHCAP/HAP cases. Considering the difficulty of accurate diagnose of AP, it will be increasingly important to perform swallowing assessments for correct diagnosis.

Regarding the use of the antibiotics, CTRX (37.3%), SBT/ABPC (36.5%), and LVFX (11.1%), the standard choices for empiric therapy of CAP in adults [39], were frequently used in non-AP treatments of CAP: this implies targets for the treatment of non-AP patients in this study were S. pneumoniae and Haemophilus influenzae, typical causative organisms of CAP [40]. SBT/ABPC was also frequently used in the treatment of AP in CAP (64.5%), and this antibiotic is recommended for most AP patients of CAP and HAP with a low risk of drug-resistant bacteria [1, 41]. In NHCAP/HAP, the selection of the antibiotics was not significantly different between AP and non-AP patients. We suspect that the selection of antibiotics in NHCAP/HAP was performed considering the possibility of AP, even in the diagnosis of non-AP. Collectively, in this study, the tendency of empiric therapies in pneumonia patients seems generally appropriate at the present time. Novel understanding of microbiology and pathology of AP has evolved with the use of advanced technology, such as targeted polymerase-chain-reaction, sequencing of bacterial 16S ribosomal RNA genes, and metagenomics [1], and new candidate microbes of AP have been identified in the oral cavity [42]. Further studies will be needed to clearly understand the actual pathogens of AP and select appropriate antibiotics.

5. Limitation

Our study is a retrospective observational study, using clinical records of pneumonia patients in all departments of eight hospitals. Patients in this study were treated not only by pulmonologists but also by non-pulmonologists. Although this limitation of difference in therapist qualification might cause prognostic differences in pneumonia patients, Komiya et al. reported that the overall prognosis of pneumonia in elderly patients might not necessarily improve, irrespective of treatment by pulmonologists [43]. The results of this study cannot apply to non-hospitalized pneumonia patients because only hospitalized patients were enrolled. Mortality detection was limited to the inpatient setting, and we did not assess the presence of "do not resuscitate" order. Further studies, including chronic care hospitals and nursing homes, will be required to reveal the overview of AP in the future.

The strengths of this study are its large size and the multicenter, multiregional population, including both urban and rural areas. Overall, we believe that a large number of pneumonia patients and variability of clinicians involved in this study could increase the generalization of the research, compensate for the limitations of the study and provide knowledge about the clinical differences between AP and non-AP patients.

6. Conclusion

AP accounts for 38.4% of all pneumonia cases, and for 42.8% of elderly cases in acute care hospitals in Northern Japan. Lower BMI, lower C-reactive protein, a lower ratio of homestay before hospitalization, a higher complication rate of cerebrovascular disease, dementia, and neuromuscular disease were significant characteristics of AP patients compared with non-AP patients. Swallowing intervention may be associated with lowering mortality in AP patients. However, swallowing assessments, especially video endoscopy and video fluorography, are still not popular even in AP patients. With the growth of the elderly population, preventive methods such as swallowing intervention, e.g., swallowing training and oral care [4447], pharmacologic therapy [48], and sarcopenia [49], and nutrition management [50] will become more critical. All the medical doctors involved in geriatric treatment, not only pulmonologists, need to develop a better understanding of AP.

Supporting information

S1 Data

(XLSX)

Acknowledgments

The authors thank Dr. Hajime Kurosawa, professor of the department of occupational medicine, Tohoku university graduate school of medicine, for critical reading of this paper.

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

This research was supported by AMED under Grant Number 19dk0310101h0001.

References

  • 1.Mandell LA, Niederman MS. Aspiration Pneumonia. N Engl J Med. 2019;380(7):651–63. Epub 2019/02/15. doi: 10.1056/NEJMra1714562 . [DOI] [PubMed] [Google Scholar]
  • 2.Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64 Suppl 3:iii1-55. Epub 2009/10/14. doi: 10.1136/thx.2009.121434 . [DOI] [PubMed] [Google Scholar]
  • 3.Kaplan V, Angus DC, Griffin MF, Clermont G, Scott Watson R, Linde-Zwirble WT. Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med. 2002;165(6):766–72. Epub 2002/03/19. doi: 10.1164/ajrccm.165.6.2103038 . [DOI] [PubMed] [Google Scholar]
  • 4.Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med. 2001;344(9):665–71. Epub 2001/03/03. doi: 10.1056/NEJM200103013440908 . [DOI] [PubMed] [Google Scholar]
  • 5.Almirall J, Rofes L, Serra-Prat M, Icart R, Palomera E, Arreola V, et al. Oropharyngeal dysphagia is a risk factor for community-acquired pneumonia in the elderly. Eur Respir J. 2013;41(4):923–8. Epub 2012/07/28. doi: 10.1183/09031936.00019012 . [DOI] [PubMed] [Google Scholar]
  • 6.Herzig SJ, LaSalvia MT, Naidus E, Rothberg MB, Zhou W, Gurwitz JH, et al. Antipsychotics and the Risk of Aspiration Pneumonia in Individuals Hospitalized for Nonpsychiatric Conditions: A Cohort Study. J Am Geriatr Soc. 2017;65(12):2580–6. Epub 2017/11/03. doi: 10.1111/jgs.15066 ; PubMed Central PMCID: PMC5729090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Manabe T, Teramoto S, Tamiya N, Okochi J, Hizawa N. Risk Factors for Aspiration Pneumonia in Older Adults. PLoS One. 2015;10(10):e0140060. Epub 2015/10/09. doi: 10.1371/journal.pone.0140060 ; PubMed Central PMCID: PMC4596873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Noguchi S, Yatera K, Kato T, Chojin Y, Fujino Y, Akata K, et al. Impact of the number of aspiration risk factors on mortality and recurrence in community-onset pneumonia. Clin Interv Aging. 2017;12:2087–94. Epub 2017/12/22. doi: 10.2147/CIA.S150499 ; PubMed Central PMCID: PMC5724415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.van der Maarel-Wierink CD, Vanobbergen JN, Bronkhorst EM, Schols JM, de Baat C. Risk factors for aspiration pneumonia in frail older people: a systematic literature review. J Am Med Dir Assoc. 2011;12(5):344–54. Epub 2011/04/01. doi: 10.1016/j.jamda.2010.12.099 . [DOI] [PubMed] [Google Scholar]
  • 10.Teramoto S, Fukuchi Y, Sasaki H, Sato K, Sekizawa K, Matsuse T, et al. High incidence of aspiration pneumonia in community- and hospital-acquired pneumonia in hospitalized patients: a multicenter, prospective study in Japan. J Am Geriatr Soc. 2008;56(3):577–9. Epub 2008/03/05. doi: 10.1111/j.1532-5415.2008.01597.x . [DOI] [PubMed] [Google Scholar]
  • 11.Annual Report on the Ageing Society [Summary] FY 2019: Cabinet Office, Government of Japan; 2019. Available from: https://www8.cao.go.jp/kourei/english/annualreport/2019/pdf/2019.pdf.
  • 12.Vital statistics of Japan: Ministry of Health, Labour and Welfare, Japan; 2019. Available from: https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei18/xls/hyo.xls.
  • 13.Kohno S, Imamura Y, Shindo Y, Seki M, Ishida T, Teramoto S, et al. Clinical practice guidelines for nursing- and healthcare-associated pneumonia (NHCAP) [complete translation]. Respir Investig. 2013;51(2):103–26. Epub 2013/06/26. doi: 10.1016/j.resinv.2012.11.001 . [DOI] [PubMed] [Google Scholar]
  • 14.Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest. 2005;128(6):3854–62. Epub 2005/12/16. doi: 10.1378/chest.128.6.3854 . [DOI] [PubMed] [Google Scholar]
  • 15.Japanese Respiratory S. Aspiration pneumonia. Respirology. 2009;14 Suppl 2:S59–64. Epub 2009/10/28. doi: 10.1111/j.1440-1843.2009.01578.x . [DOI] [PubMed] [Google Scholar]
  • 16.Kato K, Ikeda R, Suzuki J, Hirano-Kawamoto A, Kamakura Y, Fujiu-Kurachi M, et al. Questionnaire survey on nurses and speech therapists regarding dysphagia rehabilitation in Japan. Auris Nasus Larynx. 2020. Epub 2020/08/30. doi: 10.1016/j.anl.2020.08.004 . [DOI] [PubMed] [Google Scholar]
  • 17.Trotter CL, Stuart JM, George R, Miller E. Increasing hospital admissions for pneumonia, England. Emerg Infect Dis. 2008;14(5):727–33. Epub 2008/04/29. doi: 10.3201/eid1405.071011 ; PubMed Central PMCID: PMC2600241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Komiya K, Ishii H, Umeki K, Mizunoe S, Okada F, Johkoh T, et al. Impact of aspiration pneumonia in patients with community-acquired pneumonia and healthcare-associated pneumonia: a multicenter retrospective cohort study. Respirology. 2013;18(3):514–21. Epub 2012/12/13. doi: 10.1111/resp.12029 . [DOI] [PubMed] [Google Scholar]
  • 19.Hayashi M, Iwasaki T, Yamazaki Y, Takayasu H, Tateno H, Tazawa S, et al. Clinical features and outcomes of aspiration pneumonia compared with non-aspiration pneumonia: a retrospective cohort study. J Infect Chemother. 2014;20(7):436–42. Epub 2014/05/20. doi: 10.1016/j.jiac.2014.04.002 . [DOI] [PubMed] [Google Scholar]
  • 20.Nakagawa N, Saito Y, Sasaki M, Tsuda Y, Mochizuki H, Takahashi H. Comparison of clinical profile in elderly patients with nursing and healthcare-associated pneumonia, and those with community-acquired pneumonia. Geriatr Gerontol Int. 2014;14(2):362–71. Epub 2013/07/09. doi: 10.1111/ggi.12110 . [DOI] [PubMed] [Google Scholar]
  • 21.Yamaya M, Yanai M, Ohrui T, Arai H, Sasaki H. Interventions to prevent pneumonia among older adults. J Am Geriatr Soc. 2001;49(1):85–90. Epub 2001/02/24. doi: 10.1046/j.1532-5415.2001.49015.x . [DOI] [PubMed] [Google Scholar]
  • 22.Groher ME, Bukatman R. The prevalence of swallowing disorders in two teaching hospitals. Dysphagia. 1986;1(1):3–6. doi: 10.1007/BF02408233 [DOI] [Google Scholar]
  • 23.Layne KA, Losinski DS, Zenner PM, Ament JA. Using the Fleming index of dysphagia to establish prevalence. Dysphagia. 1989;4(1):39–42. Epub 1989/01/01. doi: 10.1007/BF02407401 . [DOI] [PubMed] [Google Scholar]
  • 24.Germain I, Dufresne T, Gray-Donald K. A novel dysphagia diet improves the nutrient intake of institutionalized elders. J Am Diet Assoc. 2006;106(10):1614–23. Epub 2006/09/27. doi: 10.1016/j.jada.2006.07.008 . [DOI] [PubMed] [Google Scholar]
  • 25.Taylor JK, Fleming GB, Singanayagam A, Hill AT, Chalmers JD. Risk factors for aspiration in community-acquired pneumonia: analysis of a hospitalized UK cohort. Am J Med. 2013;126(11):995–1001. Epub 2013/09/24. doi: 10.1016/j.amjmed.2013.07.012 . [DOI] [PubMed] [Google Scholar]
  • 26.Lanspa MJ, Peyrani P, Wiemken T, Wilson EL, Ramirez JA, Dean NC. Characteristics associated with clinician diagnosis of aspiration pneumonia: a descriptive study of afflicted patients and their outcomes. J Hosp Med. 2015;10(2):90–6. Epub 2014/11/05. doi: 10.1002/jhm.2280 ; PubMed Central PMCID: PMC4310822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Lindenauer PK, Strait KM, Grady JN, Ngo CK, Parisi ML, Metersky M, et al. Variation in the Diagnosis of Aspiration Pneumonia and Association with Hospital Pneumonia Outcomes. Ann Am Thorac Soc. 2018;15(5):562–9. Epub 2018/01/04. doi: 10.1513/AnnalsATS.201709-728OC . [DOI] [PubMed] [Google Scholar]
  • 28.Komiya K, Rubin BK, Kadota JI, Mukae H, Akaba T, Moro H, et al. Prognostic implications of aspiration pneumonia in patients with community acquired pneumonia: A systematic review with meta-analysis. Sci Rep. 2016;6:38097. Epub 2016/12/08. doi: 10.1038/srep38097 ; PubMed Central PMCID: PMC5141412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Akner G, Cederholm T. Treatment of protein-energy malnutrition in chronic nonmalignant disorders. Am J Clin Nutr. 2001;74(1):6–24. Epub 2001/07/14. doi: 10.1093/ajcn/74.1.6 . [DOI] [PubMed] [Google Scholar]
  • 30.Kagansky N, Berner Y, Koren-Morag N, Perelman L, Knobler H, Levy S. Poor nutritional habits are predictors of poor outcome in very old hospitalized patients. Am J Clin Nutr. 2005;82(4):784–91; quiz 913–4. Epub 2005/10/08. doi: 10.1093/ajcn/82.4.784 . [DOI] [PubMed] [Google Scholar]
  • 31.Curran J, Groher ME. Development and dissemination of an aspiration risk reduction diet. Dysphagia. 1990;5(1):6–12. Epub 1990/01/01. doi: 10.1007/BF02407388 . [DOI] [PubMed] [Google Scholar]
  • 32.Pardoe EM. Development of a multistage diet for dysphagia. J Am Diet Assoc. 1993;93(5):568–71. Epub 1993/05/01. doi: 10.1016/0002-8223(93)91819-c . [DOI] [PubMed] [Google Scholar]
  • 33.Wright L, Cotter D, Hickson M, Frost G. Comparison of energy and protein intakes of older people consuming a texture modified diet with a normal hospital diet. J Hum Nutr Diet. 2005;18(3):213–9. Epub 2005/05/11. doi: 10.1111/j.1365-277X.2005.00605.x . [DOI] [PubMed] [Google Scholar]
  • 34.Bartlett JG, Gorbach SL, Finegold SM. The bacteriology of aspiration pneumonia. Am J Med. 1974;56(2):202–7. Epub 1974/02/01. doi: 10.1016/0002-9343(74)90598-1 . [DOI] [PubMed] [Google Scholar]
  • 35.Cesar L, Gonzalez C, Calia FM. Bacteriologic flora of aspiration-induced pulmonary infections. Arch Intern Med. 1975;135(5):711–4. Epub 1975/05/01. doi: 10.1001/archinte.135.5.711 . [DOI] [PubMed] [Google Scholar]
  • 36.Bartlett JG. How important are anaerobic bacteria in aspiration pneumonia: when should they be treated and what is optimal therapy. Infect Dis Clin North Am. 2013;27(1):149–55. Epub 2013/02/13. doi: 10.1016/j.idc.2012.11.016 . [DOI] [PubMed] [Google Scholar]
  • 37.El-Solh AA, Pietrantoni C, Bhat A, Aquilina AT, Okada M, Grover V, et al. Microbiology of severe aspiration pneumonia in institutionalized elderly. Am J Respir Crit Care Med. 2003;167(12):1650–4. Epub 2003/04/12. doi: 10.1164/rccm.200212-1543OC . [DOI] [PubMed] [Google Scholar]
  • 38.Mier L, Dreyfuss D, Darchy B, Lanore JJ, Djedaini K, Weber P, et al. Is penicillin G an adequate initial treatment for aspiration pneumonia? A prospective evaluation using a protected specimen brush and quantitative cultures. Intensive Care Med. 1993;19(5):279–84. Epub 1993/01/01. doi: 10.1007/BF01690548 . [DOI] [PubMed] [Google Scholar]
  • 39.Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45–e67. Epub 2019/10/02. doi: 10.1164/rccm.201908-1581ST ; PubMed Central PMCID: PMC6812437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Takaki M, Nakama T, Ishida M, Morimoto H, Nagasaki Y, Shiramizu R, et al. High incidence of community-acquired pneumonia among rapidly aging population in Japan: a prospective hospital-based surveillance. Jpn J Infect Dis. 2014;67(4):269–75. Epub 2014/07/25. doi: 10.7883/yoken.67.269 . [DOI] [PubMed] [Google Scholar]
  • 41.DiBardino DM, Wunderink RG. Aspiration pneumonia: a review of modern trends. J Crit Care. 2015;30(1):40–8. Epub 2014/08/19. doi: 10.1016/j.jcrc.2014.07.011 . [DOI] [PubMed] [Google Scholar]
  • 42.Boaden E, Lyons M, Singhrao SK, Dickinson H, Leathley M, Lightbody CE, et al. Oral flora in acute stroke patients: A prospective exploratory observational study. Gerodontology. 2017;34(3):343–56. Epub 2017/05/26. doi: 10.1111/ger.12271 . [DOI] [PubMed] [Google Scholar]
  • 43.Komiya K, Oka H, Ohama M, Uchida M, Miyajima H, Iwashita T, et al. Evaluation of prognostic differences in elderly patients with pneumonia treated by between pulmonologists and non-pulmonologists: a propensity score analysis. Clin Respir J. 2016;10(4):462–8. Epub 2014/11/18. doi: 10.1111/crj.12245 . [DOI] [PubMed] [Google Scholar]
  • 44.Wirth R, Dziewas R, Beck AM, Clave P, Hamdy S, Heppner HJ, et al. Oropharyngeal dysphagia in older persons—from pathophysiology to adequate intervention: a review and summary of an international expert meeting. Clin Interv Aging. 2016;11:189–208. Epub 2016/03/12. doi: 10.2147/CIA.S97481 ; PubMed Central PMCID: PMC4770066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Yoneyama T, Yoshida M, Ohrui T, Mukaiyama H, Okamoto H, Hoshiba K, et al. Oral care reduces pneumonia in older patients in nursing homes. J Am Geriatr Soc. 2002;50(3):430–3. Epub 2002/04/12. doi: 10.1046/j.1532-5415.2002.50106.x . [DOI] [PubMed] [Google Scholar]
  • 46.Tada A, Miura H. Prevention of aspiration pneumonia (AP) with oral care. Arch Gerontol Geriatr. 2012;55(1):16–21. Epub 2011/07/19. doi: 10.1016/j.archger.2011.06.029 . [DOI] [PubMed] [Google Scholar]
  • 47.Kaneoka A, Pisegna JM, Miloro KV, Lo M, Saito H, Riquelme LF, et al. Prevention of Healthcare-Associated Pneumonia with Oral Care in Individuals Without Mechanical Ventilation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Infect Control Hosp Epidemiol. 2015;36(8):899–906. Epub 2015/04/11. doi: 10.1017/ice.2015.77 . [DOI] [PubMed] [Google Scholar]
  • 48.Ohrui T. Preventive strategies for aspiration pneumonia in elderly disabled persons. Tohoku J Exp Med. 2005;207(1):3–12. Epub 2005/08/06. doi: 10.1620/tjem.207.3 . [DOI] [PubMed] [Google Scholar]
  • 49.Okazaki T, Ebihara S, Mori T, Izumi S, Ebihara T. Association between sarcopenia and pneumonia in older people. Geriatr Gerontol Int. 2020;20(1):7–13. Epub 2019/12/07. doi: 10.1111/ggi.13839 . [DOI] [PubMed] [Google Scholar]
  • 50.Yamaya M, Kawakami G, Momma H, Yamada A, Itoh J, Ichinose M. Effects of Nutritional Treatment on the Frequency of Pneumonia in Bedridden Patients Receiving Oral Care. Intern Med. 2020;59(2):181–92. Epub 2020/01/17. doi: 10.2169/internalmedicine.2966-19 ; PubMed Central PMCID: PMC7008047. [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Joseph Donlan

28 Apr 2021

PONE-D-21-00691

Characteristics of aspiration pneumonia patients in acute care hospitals: a multicenter, retrospective survey in Northern Japan

PLOS ONE

Dear Dr. Ikeda,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Your manuscript was assessed by two external experts who have raised several important concerns about the methodology and statistical analyses used, as well as the extent to which the conclusions as written are supported by the results.

Please submit your revised manuscript by Jun 12 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter..

We look forward to receiving your revised manuscript.

Kind regards,

Dr Joseph Donlan

Senior Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information.

3. Thank you for stating the following in the Funding Section of your manuscript:

"This research was supported by AMED under Grant Number 19dk0310101h0001."

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

"No"

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. Thank you for stating the following in your Competing Interests section: 

"No"

Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state "The authors have declared that no competing interests exist.", as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now

 This information should be included in your cover letter; we will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

5. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

6. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

7. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

8.  We note that Figure 1 in your submission contain map images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

8.1.    You may seek permission from the original copyright holder of Figure 1 to publish the content specifically under the CC BY 4.0 license. 

We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text:

“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”

Please upload the completed Content Permission Form or other proof of granted permissions as an "Other" file with your submission.

In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

8.2.    If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

The following resources for replacing copyrighted map figures may be helpful:

USGS National Map Viewer (public domain): http://viewer.nationalmap.gov/viewer/

The Gateway to Astronaut Photography of Earth (public domain): http://eol.jsc.nasa.gov/sseop/clickmap/

Maps at the CIA (public domain): https://www.cia.gov/library/publications/the-world-factbook/index.html and https://www.cia.gov/library/publications/cia-maps-publications/index.html

NASA Earth Observatory (public domain): http://earthobservatory.nasa.gov/

Landsat: http://landsat.visibleearth.nasa.gov/

USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): http://eros.usgs.gov/#

Natural Earth (public domain): http://www.naturalearthdata.com/

9. Please include a separate caption for each figure in your manuscript.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The paper is primarily descriptive. However, the authors do use statistics such as The Student's t-test, the Wilcoxon–Mann–Whitney test, or Fisher's exact test. All analyses are univariate. Tables 1 to 5 list many clinical and pathologic characteristics of the study sample. No attempt has been made at any statistical sophistication examining the variables of interest in a multivariate framework considering the confounding factors on any well defined endpoints.

For example the authors note that the present study revealed that swallowing interventions significantly changed the dietary pattern from a normal diet to a modified diet. Also they state that malnutrition is common in elderly people, especially those with chronic disorders , and is associated with poor hospitalization outcomes. Some adjustment of odds ratios through routine logistic analyses could have been attempted. The manuscript should be re-examined from the statistical perspective with appropriate adjustment of the important variables of interest on perhaps differentiating between AP and non AP pneumonia. The sample size is certainly large enough.

Reviewer #2: In, “Characteristics of aspiration pneumonia patients in acute care hospitals: a multicenter, retrospective survey in Northern Japan,” Suzuki and colleagues characterize hospitalized adults with pneumonia, comparing aspiration pneumonia to non-aspiration pneumonia.

Major:

1. Abstract, Results: “Swallowing intervention improved in-hospital mortality.” This study is not designed to allow such an inference. Please revise to, “Swallowing intervention was associated with lower in-hospital mortality.”

2. The microbiologic comparison of aspiration and non-aspiration pneumonia is methodologically flawed. These cohorts have different composition with respect to nursing-home or hospital status. The correct comparison should really be community acquired aspiration pneumonia vs. community-acquired non-aspiration pneumonia, and nursing home/healthcare-associated aspiration pneumonia vs. nursing home/healthcare-associated non-aspiration pneumonia. It is unsurprising that table 4 demonstrates different microbiological patterns. What would be more interested is whether aspiration patients have any different microbiologic patterns that transcend their designation to community, hospital, or nursing home. Similarly, the antibiotic patterns are not as informative when aspiration pneumonia has a higher proportion of NHCAP. After doing these analyses, the discussion should also be revised accordingly.

3. Section 4.4 is a substantial leap from the data. There are several other possible explanations for this association, including confounding by indication, selection bias, etc. While it is an interesting speculation, and may be true that swallowing intervention might reduce mortality, your study cannot demonstrate this. Please revise this section to avoid overstating conclusions and restrict the discussion to avoid unsubstantiated claims

Minor:

1. Line 221: “in patients” is written with strikethrough.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Jul 30;16(7):e0254261. doi: 10.1371/journal.pone.0254261.r002

Author response to Decision Letter 0


10 Jun 2021

Journal Requirements:

Q1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

A1. OK

Q2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information.

A2. All data were fully anonymized, and IRB in our institution waived the requirement for informed consent.

Q3. Thank you for stating the following in the Funding Section of your manuscript:

"This research was supported by AMED under Grant Number 19dk0310101h0001."

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

"No"

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

A3. We have removed the funding-related text from the manuscript and request you to update our Funding Statement as follows: This research was supported by AMED under Grant Number 19dk0310101h0001. We have also included our amended statements within our cover letter.

Q4. Thank you for stating the following in your Competing Interests section:

"No"

Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state "The authors have declared that no competing interests exist.", as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now

This information should be included in your cover letter; we will change the online submission form on your behalf.

A4. We request you to update our Competing Interests on the online submission form as follows: The authors have declared that no competing interests exist. We have also included our amended statements within our cover letter.

Q5. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

A5. We have uploaded our minimal underlying data set as Supporting Information files.

Q6. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

A6. We have removed the phrase “data not shown” in our manuscript and revised the corresponding sentence.

Q7. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

A7. Accordingly, we have removed the other ethical statement apart from the Methods section.

Q8. We note that Figure 1 in your submission contain map images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

A8. We have included maps that we created ourselves, so no copyright permission is required.

Q9. Please include a separate caption for each figure in your manuscript.

A9. We have added separate captions in Fig 1.

Reviewers' comments:

Reviewer #1:

The paper is primarily descriptive. However, the authors do use statistics such as The Student's t-test, the Wilcoxon–Mann–Whitney test, or Fisher's exact test. All analyses are univariate. Tables 1 to 5 list many clinical and pathologic characteristics of the study sample. No attempt has been made at any statistical sophistication examining the variables of interest in a multivariate framework considering the confounding factors on any well defined endpoints.

For example the authors note that the present study revealed that swallowing interventions significantly changed the dietary pattern from a normal diet to a modified diet. Also they state that malnutrition is common in elderly people, especially those with chronic disorders, and is associated with poor hospitalization outcomes. Some adjustment of odds ratios through routine logistic analyses could have been attempted. The manuscript should be re-examined from the statistical perspective with appropriate adjustment of the important variables of interest on perhaps differentiating between AP and non AP pneumonia. The sample size is certainly large enough.

Answers:

Thank you for your suggestion, and we appreciate the time and effort to provide insightful feedback to our paper. We agree with you. We have performed logistic regression analyses as to the characteristics of AP patients and swallowing intervention groups of AP patients. We showed that lower BMI, lower C-reactive protein, a lower ratio of homestay before hospitalization, a higher complication rate of cerebrovascular disease, dementia, and neuromuscular disease are significant characteristics of AP patients and that a lower ratio of AP recurrence, lower ratio of homestay before hospitalization, higher rate of swallowing assessments are significant characteristics of swallowing intervention cases in AP patients. We are grateful that the results have become more evident thanks to your comments.

Reviewer #2: In, “Characteristics of aspiration pneumonia patients in acute care hospitals: a multicenter, retrospective survey in Northern Japan,” Suzuki and colleagues characterize hospitalized adults with pneumonia, comparing aspiration pneumonia to non-aspiration pneumonia.

Major:

Q1. Abstract, Results: “Swallowing intervention improved in-hospital mortality.” This study is not designed to allow such an inference. Please revise to, “Swallowing intervention was associated with lower in-hospital mortality.”

A1. Thank you for your suggestion and, we appreciate the time and effort to provide insightful feedback to our paper. We have reflected this comment by removing the sentence “Swallowing intervention improved in-hospital mortality.” We have revised the sentences related to this point in the Abstract, Discussion, and Conclusion.

Q2. The microbiologic comparison of aspiration and non-aspiration pneumonia is methodologically flawed. These cohorts have different composition with respect to nursing-home or hospital status. The correct comparison should really be community acquired aspiration pneumonia vs. community-acquired non-aspiration pneumonia, and nursing home/healthcare-associated aspiration pneumonia vs. nursing home/healthcare-associated non-aspiration pneumonia. It is unsurprising that table 4 demonstrates different microbiological patterns. What would be more interested is whether aspiration patients have any different microbiologic patterns that transcend their designation to community, hospital, or nursing home. Similarly, the antibiotic patterns are not as informative when aspiration pneumonia has a higher proportion of NHCAP. After doing these analyses, the discussion should also be revised accordingly.

A2. We agree with you. We have performed a microbiologic comparison as you suggested: AP in CAP vs. non-AP in CAP, and AP in NHCAP/HAP vs. non-AP in NHCAP/HAP. We believe that the characteristics of causative organisms and antibiotic selection become more precise thanks to your suggestion. We have added some sentences in the Discussion section according to the new results.

Q3. Section 4.4 is a substantial leap from the data. There are several other possible explanations for this association, including confounding by indication, selection bias, etc. While it is an interesting speculation, and may be true that swallowing intervention might reduce mortality, your study cannot demonstrate this. Please revise this section to avoid overstating conclusions and restrict the discussion to avoid unsubstantiated claims

A3. We thank you for raising an important suggestion. The result of a significant decrease in in-hospital mortality in the swallowing intervention group was not supported in multivariate analysis. However, considering the limitation of this retrospective study, we speculate that swallowing intervention might reduce mortality. We have revised this section not to overstate conclusions.

Minor:

Q1. Line 221: “in patients” is written with strikethrough.

A1. We have revised the sentence.

Other points revised:

We have added Yuta Kobayashi, Akira Ohkoshi, and Ryo Ishii, who contributed to the multivariate analyses to the authors.

We have revised Figure 1 to deal with copyright issues.

We have changed “PaO2” to “SpO2” in Tables 1 and 3.

We have added Tables 2 and 4, results of multivariate analyses.

Attachment

Submitted filename: Reviewer_comments_0604.docx

Decision Letter 1

Michael J Lanspa

24 Jun 2021

Characteristics of aspiration pneumonia patients in acute care hospitals: a multicenter, retrospective survey in Northern Japan

PONE-D-21-00691R1

Dear Dr. Ikeda,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Michael J Lanspa, MD

Guest Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: (No Response)

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: (No Response)

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: (No Response)

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Acceptance letter

Michael J Lanspa

21 Jul 2021

PONE-D-21-00691R1

Characteristics of aspiration pneumonia patients in acute care hospitals: a multicenter, retrospective survey in Northern Japan

Dear Dr. Ikeda:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Michael J Lanspa

Guest Editor

PLOS ONE


Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES